August 29th 2025
Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
PSA Interpretation and Testing Can Be Made More Effective
January 1st 1995NEW YORK--Although it has revolutionized the early detection of prostate cancer, PSA testing can, and must, be improved to become the powerful tool needed in the fight against this disease, H. Ballentine Carter, MD, said at a conference on prostate cancer at Lenox Hill Hospital.
Laparoscopy May Have Limited Role In Prostate Cancer
January 1st 1995NEW YORK--Initial enthusiasm accompanying the introduction of laparoscopy in the diagnosis and treatment of prostate cancer has given way to a more realistic assessment of its value, R. Ernest Sosa, MD, said at a conference on prostate cancer at Lenox Hill Hospital. It continues to have value, but its role is limited and is unlikely to broaden.
Metastatic Prostate Cancer: Quality of Life and Cost Considerations
November 1st 1994The pharmacoeconomics of patient managementis important in the case of the critically ill. Pain palliationand improvements to quality of life are treatment goals for patientswith metastatic prostate cancer and can actually